此外，2025H1公司计提信用减值准备、资产减值准备金额共计1.21亿元，减少公司归母净利润及所有者 权益1.03亿元。 持续高水平新品研发，聚焦多联多价疫苗及创新疫苗。公司研发能力和生产规模位居国内疫苗行业前 列，25H1研发投入达3.34亿元，占营收的23.96%，多个产品进入关键临床阶段：Sabin株脊髓灰质炎灭 活疫苗（Vero细胞）、四价流感病毒裂解疫苗（3岁及以上人群）申请生产注册获得受理并完成注册现 场核查；吸附破伤风疫苗申请生产注册获得受理：吸附无细胞百白破（组分）联合疫苗、口服五价重配 轮状病毒减毒活疫苗（Vero细胞）处于III期临床、20价肺炎球菌多糖结合疫苗处于I期、Ⅱ期临床；吸 附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗（五联苗）已获得I期临床试验初步数据， 正在与药审中心沟通Ⅲ期临床事宜；吸附无细胞百白破灭活脊髓灰质炎联合疫苗、麻腮风联合减毒活疫 苗、四价肠道病毒灭活疫苗（Vero细胞）处于I期临床。此外，公司还布局了肺炎克雷伯菌疫苗、带状 疱疹疫苗、呼吸道合胞病毒疫苗等创新产品的研发，其中肺炎克雷伯菌是临床中耐药性与致病力极强的 细菌之一，对碳青霉烯类抗生素耐药的肺炎 ...

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 2.65 billion yuan, a year-on-year decrease of 23.7%, and a net profit attributable to shareholders of 200 million yuan, down 76.6% year-on-year [1] - For Q1 2025, the company reported operating revenue of 650 million yuan, an increase of 42.9% year-on-year, while the net profit attributable to shareholders was 20 million yuan, a decrease of 58.5% year-on-year [1] - The quarterly breakdown for 2024 shows operating revenues of 450 million yuan (Q1), 750 million yuan (Q2), 820 million yuan (Q3), and 630 million yuan (Q4), with corresponding net profits of 50 million yuan, 110 million yuan, 190 million yuan, and a loss of 150 million yuan [1] Group 2: Vaccine Production and Pipeline - The company experienced a mixed performance in vaccine batch approvals in 2024, with significant increases in several products, including a 3262.5% rise in human diploid rabies vaccine approvals, and a 49.9% increase in 13-valent pneumonia vaccine approvals [2] - The company has multiple products in the research pipeline, with progress reported on several vaccines, including the Sabin strain inactivated polio vaccine and the quadrivalent influenza virus split vaccine [2] - A collaboration agreement with AstraZeneca has been signed to establish a joint venture for the development of innovative vaccines [2] Group 3: Earnings Forecast - The expected earnings per share (EPS) for the company are projected to be 0.34 yuan in 2025, 0.43 yuan in 2026, and 0.52 yuan in 2027 [3]